COPD in the 21st Century
COPD in the 21st Century: Research results.
«COPD in the 21st Century» remains a major topic of discussion due to its significant impact on ill health, disability, healthcare costs and premature mortality. Scientists and clinicians across many countries have made great efforts to understand this important disease, and these have yielded positive results.
This Monograph provides an up-to-date overview of what is happening in this exciting field, both at a basic and a clinical level.
Beginning, crucially, with the patient’s perspective, the chapters that follow consider the best way to define COPD, changes in the disease’s incidence and prevalence, and offer new insights into the role of the microbiome in COPD, advances in imaging and treatment options, both pharmacological and non-pharmacological.
Taken together, these chapters are an important contribution to the Monograph series and the COPD field in general.
Contribution of Cátedra de Salud Respiratoria in "COPD in the 21st Century"
Alvar Agustì and Rosa Faner are part of this book, being authors of chapter 4: A new understanding of the natural history of COPD 45.
Read more details at
Noticias relacionadas
Coffee Talk: CADSET-explaining the lung function tracker tool
The latest episode of Coffee Talk sees co-chairs of the ERS Clinical Research Collaboration CADSET, Prof. Erik Melén and Prof. Rosa Faner, catch up to discuss the topic of the new lung function tracker tool.
Lung Tissue Multi-Layer Network Analysis Uncovers the Molecular Heterogeneity of COPD
Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous condition. We hypothesized that the unbiased integration of different COPD lung omics using a novel multi-layer approach may unravel mechanisms associated with clinical characteristics.
Microbiological Monitoring in Therapeutic Trials in Chronic Obstructive Pulmonary Disease
Insight into the impact of doxycycline in therapeutic trials for COPD, emphasizing the need for careful microbiological monitoring in future interventional trials in patients with COPD
Artículos
COPD
- 759785·Richard Beasley et Al – Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness
- 759788·Alvar Agustí, Rod Hughes, Eleni Rapsomaki, Barry Make, Ricardo Del Olmo, Alberto Papi, David Price, Laura Benton, Stefan Franzen, Jørgen Vestbo, Hana Mullerova – The many faces of COPD in real life: a longitudinal analysis of the NOVELTY cohort
- 759883·Alberto Papi, Rosa Faner, Ian Pavord, Federico Baraldi, Vanessa M McDonald, Mike Thomas, Marc Miravitlles, Nicholas Roche, Alvar Agustí. – From treatable traits to GETomics in airway disease: moving towards clinical practice
- 768799·Surya P Bhatt Richard Casaburi Alvar Agusti et Al. Chronic obstructive pulmonary disease: hiding in plain sight, a Statement from the COPD Foundation Medical and Scientific Advisory Committee
- 768885·Miguel Angel Martinez-García, Alvar Agustí. – Microbiological Monitoring in Therapeutic Trials in Chronic Obstructive Pulmonary Disease
Estudios
- 759689·Kilian Vellvé et Alt.- Pulmonary vascular reactivity in growth restricted fetuses using computational modelling and machine learning analysis of fetal Doppler waveforms.
- 769273· Singh D, Criner GJ, Agustí A et al. Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis
- 769685·Nuria Olvera et Al.- Lung Tissue Multi-Layer Network Analysis Uncovers the Molecular Heterogeneity of COPD
- 769799·Alvar Agusti, Peter G. Gibson, Vanessa M. McDonald. Treatable Traits in Airway Disease: From Theory to Practice
- 778991·Mona Bafadhel, Rosa Faner, Camille Taillé, Richard E.K. Russell, Tobias Welte, Peter J. Barnes and Alvar Agustí. Inhaled corticosteroids for the treatment of COVID-19
Imagen realizada con photoshop.
